For localized information and support, would you like to switch to your country-specific website for {0}?
Key takeaways
- It is time to move away from a reactive approach, toward a proactive, community-based model; the goal must be to intercept HF before it progresses to symptomatic disease
- The referral process and high demand for echocardiography creates significant waiting times; adding risk-prediction models to diagnostic algorithms could help to ensure high-risk patients are prioritized
- NT-proBNP testing retains a pivotal role, particularly at point of care and when combined with the latest digital technologies; however, cut-off thresholds for certain patient groups should be adjusted
About Heart Failure 2026 Congress
The Heart Failure Congress, organized by the Heart Failure Association of the ESC, is one of the leading scientific meetings dedicated to heart failure research and clinical practice.
Roche Diagnostics participated in Heart Failure 2026 through a sponsored symposium and its presence at Exhibition Booth B230. Contributions to the scientific program included one moderated poster and one sponsored symposium, bringing together experts to discuss developments in heart failure diagnostics and patient management.
Meet the speakers
Prof. Antoni Bayes-Genis
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Prof. Clare Taylor
University of Birmingham, Birmingham, UK
Dr. Ambarish Pandey
UT Southwestern Medical Center, Dallas, Texas, USA
